Email
Print
Paclitaxel Injection Market Size is estimated to reach $9.4 billion by 2028 and it is poised to grow at a CAGR of 13.2% over the forecast period of 2023-2028. According to a study by Experimental Hematology &
Oncology, pathological complete response rates for trials of neoadjuvant
nab-paclitaxel-containing regimens ranged from 5.7 to 53%. As per dose and
treatment, the median overall survival for metastatic breast cancer research
ranged from 10.8 to 23.5 months. Essential benefits of paclitaxel injection include quick results, ease of
accessibility, greater adequacy as well as accuracy and rising efficiency for
the treatment of breast cancer compared to other diseases. Paclitaxel injections
are still showing promising results in treating breast cancer. Patients with
metastatic breast cancer frequently receive treatment with the drug paclitaxel
(MBC). The surfactants, solvents and albumin used in paclitaxel formulations
are all sourced from human blood. It is believed that the addition of
co-solvents, such as polyoxyethylated castor oil, increases the toxicity
profile, causes hypersensitivity reactions, causes plasticizers from
polyvinyl chloride bags and makes infusion sets seep out. The first-line chemotherapy drug, paclitaxel, is used to treat some of the most prevalent solid tumors. The growing awareness about the role of Paclitaxel
injection in increasing human and rodent sensory neuron responses is one of the
major factors propelling the market growth.
Paclitaxel Injection Market Drivers
Increasing Prevalence of Venous Diseases and New Product Approvals:
The rise in awareness about the diseases, the growing importance of early diagnosis and increased spending on chronic diseases and venous diseases are poised to boost the market growth. Moreover, the key players in the market are investing in the research and development of technologically advanced products. These products are cost-effective and of high quality. Due to these reasons, the demand for the Paclitaxel Injection market is growing. ABRAXANE has received FDA approval as the first-line treatment for non-small cell lung cancer in individuals who are not candidates for curative surgery or radiation therapy. A multicenter, randomized, open-label study including 1,052 chemonaive patients with Stage IIIb/IV non-small cell lung cancer served as the foundation for the FDA's approval of Abraxane for this kind of cancer.
For More Queries About "Paclitaxel Injection Market" @ https://www.industryarc.com/support.php?id=17536
Growing Awareness about the Efficiency of Paclitaxel Injection:
According to the BMC Cancer research report 2021, Paclitaxel was administered to a
total of 1,966 patients weekly, 1,190 patients three times weekly and 99
patients twice weekly. The overall incidence rates of all-grade neutropenia,
leukopenia, peripheral sensory neuropathy and fatigue were 52%, 58%, 58% and
49%, respectively. The overall response rate (ORR) is 40%. Higher fundamental
benefits of paclitaxel injection include quick results, ease of accessibility,
better adequacy as well as accuracy and rising efficiency for the treatment of
cancer over other medications. These are some of the key factors that are propelling the growth of the paclitaxel injection market. Due to the
growing effectiveness of Paclitaxel Injections on patients compared to other
products, they are increasingly being adopted across the world.
Product Launch
On 12th April 2022, Apotex Corp. launched Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane® in the United States. Paclitaxel protein-bound particles for injectable suspension are indicated for the treatment of metastatic breast cancer, non-small cell lung cancer and adenocarcinoma of the pancreas.
The
Major Players in The Market
The major players in the Paclitaxel Injection Market include Bristol Myers Squibb, Sagent Pharmaceuticals, Celgene Corporation, Abbott Laboratories, Oncology Ltd, Fresenius Kabi Oncology Ltd, Luye Pharma Group, Strides Arcolab Ltd., Apotex Corp and Pfizer.